Glenn Larkin

Mar 1, 2024 | investors.com | Glenn Larkin

Akamai Technologies (AKAM) had its Relative Strength (RS) Rating upgraded from 68 to 73 Friday -- a welcome improvement, but still shy of the 80 or higher score you prefer to see. XIBD's proprietary RS Rating identifies market leadership by showing how a stock's price action over the last 52 weeks compares to that of the other stocks in our database. Decades of market research shows that the market's biggest winners tend to have an RS Rating north of 80 in the early stages of their moves.

Feb 28, 2024 | investors.com | Glenn Larkin

XThis unique rating tracks market leadership by showing how a stock's price movement over the last 52 weeks measures up against that of other stocks on the major indexes. Decades of market research shows that the market's biggest winners typically have an 80 or better RS Rating in the early stages of their moves. Fortinet is still trying to complete a cup with handle with a 73.91 buy point. It recently teased hitting the pivot before falling back.

Feb 27, 2024 | investors.com | Glenn Larkin

One important metric to look for in a stock is an 80 or higher Relative Strength Rating. Lemonade (LMND) now clears that threshold, with a jump from 72 to 87 Tuesday. XIBD's unique rating identifies price movement with a 1 (worst) to 99 (best) score. The rating shows how a stock's price behavior over the trailing 52 weeks holds up against all the other stocks in our database.

Feb 26, 2024 | investors.com | Glenn Larkin

XIBD's proprietary RS Rating tracks technical performance by using a 1 (worst) to 99 (best) score that indicates how a stock's price action over the last 52 weeks matches up against other publicly traded companies. Decades of market research shows that the market's biggest winners typically have an 80 or higher RS Rating in the early stages of their moves. GE HealthCare Techs is still in a buy range after breaking past an 87.83 entry in a consolidation.

Feb 23, 2024 | investors.com | Glenn Larkin

Notice: Information contained herein is not and should not be construed as an offer, solicitation, or recommendation to buy or sell securities. The information has been obtained from sources we believe to be reliable; however no guarantee is made or implied with respect to its accuracy, timeliness, or completeness. Authors may own the stocks they discuss. The information and content are subject to change without notice. *Real-time prices by Nasdaq Last Sale.